Industry News
Merck-Keytruda
Merck would like to inform you that WELIREG, in combination with KEYTRUDA or KEYTRUDA QLEX,…
NCCN introduces a New Payer Resource
NCCN has introduced a Payer Relations Resource Page, which provides information on the intended use of…
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD)…
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
In the trial, oral mezigdomide in combination with carfilzomib and dexamethasone (MeziKd) demonstrated statistically…
AstraZeneca announces a new FDA approval for new treatment regimen for CALQUENCE® (acalabrutinib)
Astrazeneca is pleased to announce that the US Food and Drug Administration (FDA) has approved…